Peptides. An Honest Guide

A peptide is a short chain of amino acids linked by peptide bonds. That is the same chemistry that builds every protein in your body. The line between peptide and protein is fuzzy on purpose. By IUPAC convention, chains of 10 or more residues are called polypeptides ^[2]. Once a chain folds into a stable three-dimensional shape (usually around 50 residues, or roughly 5 kilodaltons), most chemists start calling it a protein. Insulin sits right on that border at 51 amino acids in two disulfide-linked chains, and gets called both.

What matters biologically is not the length. It is the chemistry. The peptide bond is flat and partly rigid: it has about 40 percent double-bond character (a planar amide, in chemistry terms). That one fact decides how peptides fold, how they signal, and why your gut destroys most of them on contact. Almost all natural peptides are built from L-stereoisomer amino acids (the left-handed mirror image), and your digestive enzymes evolved to recognize that exact handedness.

Your body uses peptides as signaling molecules everywhere. Insulin controls blood sugar. Glucagon raises it. Oxytocin drives childbirth and social bonding. Vasopressin controls water retention. GnRH triggers reproductive hormones. Ghrelin signals hunger. GLP-1 is the gut hormone behind Ozempic and Wegovy. Somatostatin turns off other hormones. ANP and BNP regulate fluid balance and double as heart-failure markers. Beta-endorphin is your body's own opioid. Substance P signals pain.

Why most peptides get injected, not swallowed. Native peptides have plasma half-lives measured in minutes. Natural GLP-1 lasts about 1 to 2 minutes once released, before an enzyme called DPP-4 cuts it apart. Swallow a peptide and your gut breaks it down. Even oral semaglutide (Rybelsus, FDA-approved 2019) gets only about 1 percent of the dose into your bloodstream. It works because it is unusually potent. Most peptide drugs are injectables for a reason.

Peptide therapy has a hundred-year arc. Here are the turning points.

1921. Banting and Best at the University of Toronto isolate insulin from canine pancreas. The first peptide ever used as a human drug, and still the most important. Nobel 1923.

1953. Vincent du Vigneaud chemically synthesizes oxytocin, the first peptide hormone built from individual amino acids in a lab. Nobel 1955.

1963. Bruce Merrifield publishes solid-phase peptide synthesis in JACS, anchoring the growing chain to a polymer bead. This was the manufacturing leap that made every modern peptide drug commercially possible. Nobel 1984.

1982. FDA approves Humulin (Genentech / Eli Lilly), recombinant human insulin grown in E. coli. The first genetically engineered medicine ever approved, reviewed in five months versus the roughly 30-month average of the era.

1985. Doctors recognize iatrogenic Creutzfeldt-Jakob disease (a fatal prion brain disease) in young recipients of cadaver-derived pituitary growth hormone. The program shuts down. Recombinant somatropin (Genentech's Protropin, also 1985) replaces it.

1985 / 1988. FDA approves leuprolide, opening the GnRH-agonist era for prostate cancer and endometriosis. Then comes octreotide, the first somatostatin analog and a turning point in treating acromegaly.

1992. John Eng at the Bronx VA isolates exendin-4 from the saliva of Heloderma suspectum, the Gila monster. This desert lizard fasts for months without crashing its blood sugar. The molecule became the template for the entire GLP-1 drug class ^[3]. Eng patented it himself because the VA would not.

1993. Predrag Sikiric in Zagreb describes BPC-157, a 15-amino-acid peptide claimed to be a fragment of a 'body protection compound' in human gastric juice. The entire grey-market 'research peptide' subculture traces back to this one Croatian lab.

2005 to 2022. The GLP-1 dynasty arrives in order: exenatide (Byetta, 2005), liraglutide (Victoza/Saxenda, 2010), semaglutide (Ozempic 2017, Wegovy 2021), tirzepatide (Mounjaro/Zepbound, a dual GIP/GLP-1, 2022). The Gila-monster lineage became the fastest-growing drug class in pharma history.

September 2023. The FDA moves a cluster of grey-market peptides into Category 2 of the 503A interim bulks list ^[6]. That means US compounding pharmacies (pharmacies that mix drugs to order) can no longer use them. The list: BPC-157, TB-500/thymosin β4, MOTS-c, KPV, epitalon, Selank, Semax, DSIP, AOD-9604, GHK-Cu (injectable), Melanotan II, PEG-MGF, CJC-1295 with DAC, ipamorelin, GHRP-2, GHRP-6. The crackdown is on.

2024 to 2026. The FDA declares the tirzepatide and semaglutide shortages resolved (Dec 2024 and Feb 2025), ending the grey legal route for compounded GLP-1s. From September 2025 the FDA sends a wave of warning letters to telehealth GLP-1 sellers, and in March 2026 it announces warnings to 30 more companies ^[22]. Novo Nordisk sues Hims & Hers in February 2026, then settles a month later. By April 2026 the nominations for BPC-157 and 16 other peptides have been withdrawn by the people who submitted them, and the FDA lists them in a separate section ^[6].

July 2026. On 23 and 24 July the FDA's Pharmacy Compounding Advisory Committee reviews seven of these peptides ^[23]. It narrowly votes to let US compounding pharmacies use six: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. It rejects DSIP. FDA staff reviewers had argued there was not enough evidence to judge safety and effectiveness. The vote is advisory. As of September 2026 the FDA has not decided, and none of these peptides is an approved drug.

Hear 'peptide therapy' and many people picture grey-market vials and influencer protocols. The reality is the opposite. Peptides are one of the most established and tightly regulated drug classes in modern medicine. Roughly 100 peptide drugs are approved globally as of 2026 ^[1], and they sit at the center of mainstream care.

Diabetes and obesity. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta). All peptide drugs.

Hormone replacement. Insulin and its analogs (lispro, aspart, glargine, degludec). Glucagon (Baqsimi nasal, Gvoke SC) for severe hypoglycemia. Recombinant growth hormone (somatropin). Teriparatide (Forteo) and abaloparatide (Tymlos), both anabolic peptides for osteoporosis at fracture risk.

Prostate cancer and endometriosis. GnRH agonists: leuprolide (Lupron), goserelin (Zoladex), triptorelin. GnRH antagonists: degarelix (Firmagon), relugolix (Orgovyx, the first oral GnRH antagonist, FDA 2020).

Acromegaly and neuroendocrine tumors. Somatostatin analogs: octreotide (Sandostatin), lanreotide (Somatuline), pasireotide (Signifor).

Other approved indications. Desmopressin (DDAVP) for central diabetes insipidus and nocturnal enuresis. Setmelanotide (Imcivree) for rare genetic obesity. Bremelanotide (Vyleesi) for premenopausal HSDD (hypoactive sexual desire disorder). Linaclotide (Linzess) and plecanatide (Trulance) for IBS-with-constipation. Calcitonin (Miacalcin) for hypercalcemia and Paget's. Elamipretide (FDA 2025) for Barth syndrome, a mitochondria-targeted tetrapeptide.

Antibiotics that are peptides. Vancomycin (1958), daptomycin (2003), polymyxin B and colistin, teicoplanin. These are the backbone of MRSA, VRE, and Gram-negative bacterial therapy.

Two non-obvious facts. First, the entire GLP-1 phenomenon traces to Gila monster venom, a desert reptile that fasts for months. Second, oral peptides are no longer impossible. Oral semaglutide (Rybelsus, 2019) and oral octreotide (Mycapssa, 2020) broke the long-standing dogma that peptides only work by injection. The next decade of peptide drugs will increasingly be pills, not pens.

The 'peptide revolution' is not coming. It already happened, over the last forty years.

Outside the pharmacy, the conversation is very different. The grey-market longevity stack is roughly a dozen injectable peptides (BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295, MOTS-c, epitalon and others) sold by US compounding clinics, telehealth sites, and 'research peptide' vendors. Only two are well-evidenced (tesamorelin, thymosin α1). Most sit between 'promising in mice' and 'pure marketing'. Here is what the stack usually includes:

• BPC-157. A 15-amino-acid synthetic peptide marketed for joint, tendon, and gut healing. About 230 papers are indexed in PubMed, and roughly three in four list Sikiric or Seiwerth (Univ. of Zagreb) as an author (PubMed search, September 2026). Independent replications in mainstream journals are sparse. Only three small pilot studies in humans have been published ^[4]. No Phase II or III trial anywhere. Placed on FDA 503A Category 2 in September 2023 (FDA cited immunogenicity, peptide-related impurities, and no adequate human safety data) ^[6]. Added to the WADA S0 (non-approved substances) category effective 1 January 2022 ^{[5, 17]}.
• Thymosin β4 / TB-500. Actin-binding peptide claimed to repair tissue. RegeneRx ran legitimate Phase 2 trials (paused for funding, not safety). FDA Category 2 from 2023; banned by WADA under S2 (peptide hormones and growth factors).
• Thymosin α1 (Tα1, Zadaxin). The strongest evidence on this list. Approved in 35+ countries (Italy for melanoma adjuvant, China for hepatitis B). Over 11,000 patients across published trials. Not FDA-approved.
• Sermorelin (GHRH 1-29). FDA-approved in 1997 as Geref for pediatric GH deficiency (a diagnostic version since 1990). EMD Serono discontinued it in 2008. In 2013 the FDA formally determined it was not withdrawn for safety or effectiveness reasons ^[13]. Compounded only since then.
• Tesamorelin (Egrifta / Egrifta WR). Stabilized GHRH analog, FDA-approved 2010 for HIV-associated visceral lipodystrophy. The legitimate GHRH analog. Its EMA application was withdrawn in 2012, after the EMA's expert committee (CHMP) doubted the benefit was clinically meaningful and flagged rising IGF-1 levels ^[24].
• Ipamorelin. Selective GHS-R (ghrelin) agonist, never FDA-approved. Failed Phase 2 in postoperative ileus. In FDA Category 2 since September 2023.
• CJC-1295 with DAC. Long-acting GHRH analog (DAC is a chemical add-on that keeps it in the blood for days). ConjuChem's Phase 2 in HIV lipodystrophy was halted in July 2006 after a participant death. The participant died of a myocardial infarction (heart attack) roughly two hours after the 11th dose. The trial physician judged it likely unrelated and attributed it to asymptomatic coronary disease. Development was abandoned anyway, as a precaution.
• MOTS-c. A 16-amino-acid mitochondrial-derived peptide (Cohen lab, USC, 2015). Genuine mainstream research interest. CohBar took CB4211 to Phase 1, then dissolved in 2023. Solid mouse data, no human longevity trials.
• Humanin. A 24-amino-acid mitochondrial peptide (Hashimoto, 2001) ^[36], mostly preclinical.
• Epitalon (AEDG). Tetrapeptide claimed to extend telomeres. Almost entirely from one Russian group (Khavinson, St Petersburg). Essentially zero independent Western replications.
• GHK-Cu. Copper tripeptide. Topical use (skincare) has decent small-trial data. Injectable use has no human RCTs.
• AOD-9604. GH fragment marketed for fat loss. Failed Phase 2b in 2007 (no significant weight effect at 24 weeks in n=536). Resurrected by clinics with no new evidence.
• Selank, Semax. Registered in Russia as prescription nootropics (drugs sold to sharpen thinking). Everywhere else, research chemicals.
• Cerebrolysin. Porcine brain-derived peptide cocktail. Approved in around 50 countries (Austria included), not FDA. Cochrane reviews find weak, industry-funded evidence with benefit 'too small to be clinically meaningful'.

One-line summary: two of these are well-evidenced (tesamorelin, thymosin α1), one is mechanistically interesting and worth watching (MOTS-c), and most of the rest sit somewhere between 'promising in mice' and 'marketing'.

Most clinic peptide protocols (sermorelin, ipamorelin, CJC-1295) raise GH and IGF-1 by 50 to 100 percent. Yet the most replicated finding in longevity biology says lower lifetime GH/IGF-1 signaling goes with a longer healthspan (years lived in good health) and a longer life. So the marketed mechanism runs the longevity experiment in reverse. That is the IGF-1 paradox, and it is the section longevity-clinic websites avoid.

Most grey-market longevity peptide protocols revolve around the GH/IGF-1 axis: sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677. They all do roughly the same thing. They push your pituitary to release more growth hormone, which then raises IGF-1 (insulin-like growth factor 1, the downstream signaling molecule) in the liver.

The evidence runs from worms to humans. Lower lifetime GH/IGF-1 signaling correlates with longer healthspan and longer life:

• C. elegans roundworms with loss-of-function mutations in daf-2 (the worm's insulin/IGF-1 receptor gene, its version of IGF-1R) live up to twice as long (Kenyon, 1993).
• Ames and Snell dwarf mice make very little GH and live up to roughly 50 to 65 percent longer than wild-type mice (Bartke). The two strains carry different mutations: Prop1 in Ames, Pit1/Pou1f1 in Snell.
• The Guevara-Aguirre Ecuadorian Laron-syndrome cohort (humans with non-functioning GH receptors and near-zero IGF-1) has been followed for over 22 years. Despite obesity, the cohort shows essentially zero diabetes and one non-lethal cancer, versus 5 percent diabetes and 17 percent cancer in unaffected relatives (Sci Transl Med, 2011) ^[9].
• Women in their 90s with below-median IGF-1 survived significantly longer than those above the median. Men showed no such difference (Milman & Barzilai, Aging Cell, 2014, n = 184) ^[10]. FOXO3, which sits downstream of IGF-1R and switches on when IGF-1 signaling is low, is the most replicated longevity gene in humans.
• Acromegaly (the disease state of chronically high GH and IGF-1) raises cancer risk. A 2023 meta-analysis found thyroid cancer at around 7x the expected rate (standardized incidence ratio, SIR) and colorectal cancer at 1.95x (PLOS One 2023) ^[31]. A nationwide Danish cohort found a smaller rise and warned that older single-centre studies overstate it (JCEM 2018) ^[32].

And one more wrinkle: in the 2023 update to the Hallmarks of Aging (López-Otín et al., Cell) ^[11], 'disabled macroautophagy' was added as a standalone hallmark. GH-axis peptides activate mTORC1 (the cell's main growth switch), which suppresses autophagy (your cells' built-in recycling program for damaged proteins). They push against this hallmark.

Put it together. A healthy adult pays €500-1500 a month at a clinic to pulse GHRH and ghrelin agonists (drugs that push the pituitary to release GH). IGF-1 rises 50-100 percent, mTORC1 switches on, and autophagy is suppressed. That person is running the longevity experiment in reverse. The acute effects users notice (better sleep, leaner body composition, faster recovery) are real and short-term. The mechanism they activate is the one nature appears to down-regulate in long-lived humans and animals. There is no human RCT showing GH-axis peptides extend lifespan. The biology argues they may compress it.

The risks of grey-market peptide use are not theoretical. They have a body count.

Contamination and mislabeling. A 2024 study in the Journal of Medical Internet Research (Ashraf et al.) bought 'semaglutide' vials without a prescription from three online vendors (SemaSpace, BiotechPeptides, USChemLabs) and tested them ^[7].

• Purity: 7.7 to 14.4 percent measured polypeptide purity, versus at least 99 percent claimed.
• Endotoxin (bacterial debris that causes fever, sepsis, and septic shock when injected): detected in all three vials, from 2.16 to 8.95 EU/mg (endotoxin units per milligram). The study reads the highest level (8.95 EU/mg, SemaSpace) as a sign of contamination during production.
• Dose: in all three vials the semaglutide content exceeded the labelled dose by 28 to 39 percent. That is an overdose risk on top of the impurity problem.
• Not tested: heavy metals.

One caveat on the endotoxin numbers. The paper does not compare them with a pharmacopeial limit for injectables. The USP chapter 85 limit is set per dose, not as one fixed EU/mg cutoff. So the proven problem is an uncontrolled, unsanitary process, not a measured breach of a numeric limit.

Independent tests of other 'research' peptide vials have found wrong amino-acid sequences and racemized D/L stereoisomers (mirror-image versions of the amino acids, a known trigger for immune reactions). They have also found Certificates of Analysis that were fabricated, copy-pasted between products, or attached to the wrong substance entirely.

Counterfeit GLP-1s. Three named events.

• WHO Medical Product Alert N°2 / 2024 (19 June 2024): falsified Ozempic batches LP6F832, NAR0074, and MP5E511 identified in the regulated supply chain in Brazil, the UK, and the US (Oct to Dec 2023) ^[8]. The WHO alert itself does not name the substituted ingredient, but parallel regulatory and press reporting (Austrian and Lebanese authorities, US case series) documented hospitalisations from severe hypoglycemia after counterfeit pens later confirmed to contain insulin instead of semaglutide.
• MHRA Birmingham notice (24 February 2026): five falsified Mounjaro KwikPen 15mg pens (batch D873576) identified at The Private Pharmacy Clinic after dose-knob faults. The clinic informed individual patients ^[20].
• Salford death (May 2025): Karen McGonigal, 53, of Salford (Greater Manchester) received an illegal £20 weight-loss injection from a beautician. The substance was reported as believed to be semaglutide. She was hospitalised four days after her last injection and died after two days in intensive care. Greater Manchester Police arrested two people, one on suspicion of manslaughter and one on suspicion of supplying a controlled substance ^[19].

FAERS and FDA enforcement. FAERS is the FDA's database of reported side effects. As of 31 May 2026 the FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, some requiring hospitalization ^[29]. Reports show association, not proven causation. A common pattern: patients drew 5 to 20x the intended dose from multidose vials.

From September 2025 the FDA sent a wave of warning letters to telehealth GLP-1 sellers. Letters to another 30 companies went out on 20 February 2026 (publicly announced 3 March 2026) ^[22].

One older case is still the most-cited US precedent on unapproved-peptide forfeiture. After a 2020 plea agreement and 2021 sentencing, the Department of Justice obtained a $1.79 million criminal forfeiture against Tailor Made Compounding (Nicholasville, Kentucky). The company had distributed BPC-157 and 13 other unapproved drugs (several of them SARMs, not peptides). The case predates the current FDA telehealth crackdown.

Systemic risks of GH-axis peptides. Acromegaly (the chronic-high-GH disease state these peptides simulate at supraphysiologic doses) raises cancer risk: thyroid cancer at around 7x the expected rate and colorectal cancer at 1.95x (SIR 1.95) in a 2023 meta-analysis ^[31], though a nationwide Danish cohort found a smaller rise ^[32]. Water retention, peripheral edema, carpal tunnel from median-nerve compression, insulin resistance, hypothyroidism, and pituitary axis suppression all show up in healthy users. A 24-week Phase IIb trial of MK-677 (ibutamoren) in 123 older adults recovering from a hip fracture was stopped early because of a heart-failure safety signal (6.5% versus 1.7% placebo) ^[27].

Pro-angiogenic peptides and cancer. BPC-157 and TB-500 work in part by stimulating angiogenesis (the growth of new blood vessels). VEGF/VEGFR2, the main pathway BPC-157 upregulates, is active in roughly half of human tumors. No human carcinogenicity data exists either way. The mechanism is the worry: you do not want to drive angiogenesis if there is anything malignant or pre-malignant in your body that you do not yet know about.

GLP-1 systemic risks. Even the FDA-approved versions carry real risks. A 2024 single-centre cohort study (Hathaway, Mass Eye and Ear, JAMA Ophthalmology) found a roughly 4x higher risk of NAION (non-arteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss) ^[14]. In June 2025 the EMA's safety committee (PRAC) confirmed NAION as a very rare side effect of semaglutide: roughly double the risk, affecting up to 1 in 10,000 users ^[30]. Other known risks are cholelithiasis, or gallstones (RR 1.46), and gastroparesis (a stomach that empties too slowly) severe enough to delay anesthesia. The PRAC reviewed a suicidality signal in April 2024 and did not confirm it.

Melanotan-II. Several peer-reviewed case reports document eruptive dysplastic nevi (sudden new abnormal moles), severe dysplasia on histology, and at least four melanomas arising in pre-existing nevi during or shortly after use.

Why peptides are harder to assess than small molecules. Because peptides clear the blood so fast, they defeat the standard studies that track where a drug goes and how the body clears it (mass-balance and PK studies). Immunogenicity (your immune system mounting an antibody response to the peptide) is unpredictable batch-to-batch and can be life-threatening if the antibody cross-reacts with your own endogenous version. Modified peptides (DAC, PEGylation) have no established analytical reference standards. There is no FDA-approved clinical-pharmacology package for the vast majority of grey-market peptides. You are the Phase 1 subject.

Germany, Austria, and Switzerland all treat peptides as medicines, not supplements. That legal stance matters more than most buyers realize.

Peptide legal status at a glance (September 2026):

Peptide	EU / Germany	USA	Legal route for you
Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro)	approved, prescription only	approved	prescription and pharmacy
Retatrutide ("GLP-3")	not approved	not approved, filing planned for early 2027 [39]	none
Tesamorelin	not approved (EMA application withdrawn 2012) [24]	approved (Egrifta)	single-patient import via a pharmacy on prescription (§ 73 Abs. 3 AMG) [15]
BPC-157, TB-500, MOTS-c, epitalon, Semax, KPV	not approved	not approved; advisory panel backed compounding in July 2026, FDA decision pending [23]	none
Ipamorelin, GHRP-2, GHRP-6, CJC-1295	not approved; AntiDopG quantity thresholds apply [16]	not approved; GHRP-2, GHRP-6 and ipamorelin still in Category 2 for 503B outsourcing facilities [6]	none

Germany. The relevant law is the Arzneimittelgesetz (AMG).

• § 73 AMG (Verbringungsverbot): prescription medicines cannot be mail-ordered to private individuals from outside the EU/EEA ^[15]. This is not a grey zone. German Customs (Zoll) routinely seizes peptide shipments at airports and sends recipients an Anhörungsbogen (formal hearing notice). The Zollfahndungsamt München and the Munich prosecutor's office ran a coordinated 12-defendant peptide investigation in 2024-2025.
• § 96 and § 95 AMG (Strafvorschriften): selling an unauthorized medicine is a crime under § 96 Nr. 5, with up to 1 year or a fine ^[34]. If the product counts as unsafe (bedenklich, § 5) or is prescription-only and traded outside a pharmacy (§ 43), § 95 applies: up to 3 years, and 1 to 10 years in especially serious cases such as endangering many people or large-scale profit ^[35].
• Personal travel supply (§ 73 Abs. 2 Nr. 6): when you enter Germany you may bring medicines in a quantity matching your normal personal need (in customs practice about a 3-month supply) personally in your luggage ^[15]. This does not cover postal orders.
• Single-patient import (§ 73 Abs. 3): a pharmacy may import a medicine that is not approved in Germany for one patient on prescription, if it is legally sold in the country it comes from and no comparable drug is available here ^[15]. That is the route for tesamorelin. It does not work for BPC-157, which is approved nowhere.
• Anti-Doping-Gesetz (AntiDopG, 2015). It has two kinds of offence, and they reach different people ^[33].
• Trade, and possession above a threshold (§ 4 Abs. 1 Nr. 1 to 3): manufacturing, dealing in or supplying a doping agent, and acquiring or possessing a nicht geringe Menge (non-trivial quantity) of a listed substance for doping in sport. This applies to everyone, athlete or not.
• Self-doping and small amounts (§ 4 Abs. 1 Nr. 4 and 5, Abs. 2): using a doping agent on yourself, competing while doped, or holding smaller amounts for self-doping. § 4 Abs. 7 limits these offences to Spitzensportler in an organised-sport Testpool or people earning substantial income from sport.
• Threshold quantities live in the Dopingmittel-Mengen-Verordnung (DmMV) ^[16]: GHRH analogs 180 mg, GH secretagogues/mimetics (e.g. ipamorelin) 150 mg, GHRPs (GHRP-2/6) 1.5 mg, IGF-1 analogs 3 mg, thymosin β4 and its derivatives (e.g. TB-500) 100 mg. A single vial of GHRP-2 or GHRP-6 already exceeds the 1.5 mg GHRP threshold. CJC-1295 and ipamorelin vials, typically a few milligrams, sit far below the 180 mg and 150 mg thresholds, but a stockpile can cross them.
• BPC-157 is not in the AntiDopG annex as of 2026, so AntiDopG does not apply to it and the AMG does. TB-500 is listed (thymosin β4 and its derivatives), and so is AOD-9604 (GH fragments, DmMV threshold 16 mg) ^[37].
• If you are not a competitive athlete, AntiDopG reaches you through trade or above-threshold possession. Otherwise your main criminal risk with unauthorized peptides comes from the AMG.
• Heilpraktiker may not prescribe or administer prescription medicines (§ 48 AMG with HeilprG). Any Heilpraktiker offering injectable peptide therapy with prescription-grade compounds is operating outside their scope of practice.

Austria. The Arzneiwareneinfuhrgesetz 2010 (AWEG) prohibits private import of medicines from non-EU countries. Only public pharmacies may handle small imports under § 11. AGES (the Austrian medicines agency) takes the same line as BfArM.

Switzerland. Not in the EU. Under the Heilmittelgesetz (HMG, SR 812.21) Art. 20 (2)(a), private individuals may import medicines for their own use, including by post, but only up to one month's supply for therapy ^[26]. That is stricter than Germany's roughly 3-month travel allowance. Importing for other people is not allowed. Peptides classed as doping agents are handled by Swiss Sport Integrity. In a June 2026 customs action, 23 of 46 peptide parcels were held back, 21 of them as doping agents. The other 23 had to be released because the amounts were within the legal limits ^[25]. In August 2025 Swissmedic published a public warning specifically about falsified GLP-1 and 'retatrutide kit' products sold on social media ^[21].

What is actually legal in DACH:

1. Buying a peptide authorized in the EU or in Germany (for example the GLP-1s Ozempic, Wegovy, Mounjaro) at a German, Austrian, or Swiss pharmacy with a prescription from a licensed physician. Tesamorelin and sermorelin have no EU authorization ^[24].
2. Having a pharmacy import a medicine approved abroad, such as tesamorelin, for you on prescription (§ 73 Abs. 3 AMG).
3. Ordering from an EU/EEA mail-order pharmacy in a country on the German Health Ministry's (BMG) published list of states with comparable safety standards, with a valid prescription, for a medicine authorized in Germany ^[15].
4. Carrying your normal personal supply (about 3 months in German customs practice, 1 month for Switzerland) into the country in your luggage.
5. Receiving compounded sermorelin from a German pharmacy as a Rezeptur (a medicine mixed for one patient) on private prescription, if the pharmacy can source pharmaceutical-grade substance. Typical cost: €150-300 per month.

Three common misconceptions:

• 'BPC-157 is legal in Germany because it's not in the BtMG.' False. Criminal liability for selling it comes from the AMG (§ 96 Nr. 5, and § 95 in more serious cases), not the BtMG.
• 'AntiDopG never applies to me, I'm not a competitive athlete.' Partially false. Making, dealing, and possessing more than the DmMV threshold for doping in sport (§ 4 Abs. 1 Nr. 1 to 3) apply to everyone. Only self-doping and small-amount possession for self-use (§ 4 Abs. 1 Nr. 4, Abs. 2) are limited by § 4 Abs. 7 to testing-pool athletes and people with substantial sport income.
• 'Mail-order from any EU pharmacy is fine.' False. The medicine must be authorized in Germany, and the pharmacy must be based in a country on the BMG's published list.

For related grey-zone questions on ingestible compounds see the NMN Germany guide and the rapamycin Germany guide.

The field is moving in two directions. The mature one is the next-generation GLP-1 family (retatrutide hit 28.7 percent weight loss in TRIUMPH-4), which is producing the first population-scale evidence of compressed morbidity (fewer years spent sick at the end of life). The speculative one is pure-longevity peptides (MOTS-c, FOXO4-DRI), all still preclinical with minimal human data. If the grey-market peptide story is mostly noise, the legitimate peptide pipeline is genuinely worth tracking.

Next-generation GLP-1 family. This is the only mature near-term story.

• Retatrutide (Lilly, a GLP-1 / GIP / glucagon triple agonist) reported 28.7 percent mean weight loss at 12 mg in TRIUMPH-4 (December 2025), with a separate signal of meaningful osteoarthritis pain relief. The pivotal TRIUMPH-1 trial then reported 28.3 percent mean weight loss at 12 mg after 80 weeks, and 30.3 percent at 104 weeks in people who started with a BMI of 35 or more ^[38]. Lilly plans to file with the FDA in the first quarter of 2027, so retatrutide is not approved anywhere yet ^[39]. Grey-market sellers call it "GLP-3".
• CagriSema (Novo, semaglutide combined with cagrilintide, an amylin analog) hit 22.7 percent in REDEFINE-1. Below Novo's 25 percent target, and it sent Novo's shares sharply lower in December 2024.
• Survodutide (Boehringer / Zealand, a GLP-1 / glucagon dual) achieved 16.6 percent at 76 weeks in SYNCHRONIZE-1 (April 2026), with parallel trials in MASH (fatty liver disease with inflammation).
• Orforglipron (Lilly) is a pill, and not a peptide at all. It is a small molecule that switches on the GLP-1 receptor. It is the first oral small-molecule GLP-1 with injectable-comparable efficacy, and the first non-peptide GLP-1 approved for weight loss. The FDA approved it as Foundayo on 1 April 2026 for chronic weight management in adults with obesity (or overweight with a weight-related comorbidity). The approval rests on the ATTAIN phase 3 program: more than 4,500 participants across two registration trials, around 12.4 percent mean weight loss at 72 weeks.

None of these trials use longevity endpoints. They all measure weight, A1C, cardiovascular events (SELECT: 20% fewer heart attacks, strokes and cardiovascular deaths in people with existing heart disease and overweight or obesity but no diabetes ^[28]), kidney outcomes (FLOW), MASH resolution (SYNERGY-NASH), sleep apnea (SURMOUNT-OSA, FDA approval December 2024). But the cardiometabolic spillover is functionally a longevity benefit: a single drug class now has hard outcome data on cardiovascular, renal, hepatic, sleep, and weight endpoints. Whether or not regulators ever label a drug 'anti-aging,' GLP-1s are producing the first population-scale evidence of compressed morbidity from any pharmacological agent.

Pure-longevity peptide programs. All still preclinical.

• MOTS-c lost its industrial sponsor when CohBar dissolved in 2023.
• FOXO4-DRI (the proof-of-concept senolytic peptide that selectively kills senescent cells in aged mice; Baar et al., Cell 2017) ^[12] is still pre-Phase 1 nine years on. Cleara Biotech is taking it forward.
• Klotho-domain KL1 has cognitive and renal-protective signals in models (Wyss-Coray group). No clinical-stage klotho peptide therapy yet.
• The TAME trial (the field's flagship attempt to run a real longevity RCT in humans, using metformin) remains only partially funded a decade after design. That one fact tells you why direct longevity peptide trials are rare. They are slow, expensive, and there is no FDA 'aging' indication to chase.

The biggest methodological step just landed. Validated 11-organ proteomic aging clocks (Wyss-Coray group, Nature Medicine and Nature Aging, 2025) ^[18], built from plasma proteins (GDF15, FGF21, klotho-domain KL1, and others) measured across 44,498 UK Biobank participants. They predict heart failure, COPD, type 2 diabetes, and Alzheimer onset across organ systems. They are biomarkers, not therapies, but they may make 18-month longevity trials possible where 6-year composite-endpoint trials were the only option before. That is how peptide longevity research finally gets to scale.

Where this leaves us in 2026. Peptides have produced exactly two mechanistically credible longevity threads: mitochondrial-derived peptides (MOTS-c, humanin) and senolytic peptides (FOXO4-DRI). Both come with strong preclinical data and minimal human evidence. Most clinically marketed 'longevity peptides' are either mechanistically incoherent with established aging biology, dependent on a single non-replicated research group, or sold for cosmetic and recovery effects rebadged as life extension. More data is needed, and it is probably coming. Meanwhile the GLP-1 family is doing the actual work, on actual endpoints, in actual trials.